OPTIMA: An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Participants With Chronic Kidney Disease Stages 3 and 4 Not on Dialysis
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult participants, \>/= 18 years of age
Participants with chronic kidney disease (CKD) not on dialysis with renal anemia (CKD Stages 3 \& 4)
Initiated on Mircera treatment (participants may have received Mircera treatment for up to 3 months before study enrollment)
Life expectancy \> 10 months
You may not be if
Malignant disease
Significant or acute bleeding
Poorly controlled hypertension
Blood transfusion during the previous 2 months
Hypersensitivity to Mircera or any of its excipients
Clareo Health | OPTIMA: An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Participants With Chronic Kidney Disease Stages 3 and 4 Not on Dialysis
